Teleflex (NYSE:TFX) Rating Increased to Buy at StockNews.com

Teleflex (NYSE:TFX – Get Rating) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Monday.

A number of other research firms have also commented on TFX. Needham & Company LLC restated a “buy” rating and issued a $291.00 price target on shares of Teleflex in a research report on Friday, February 24th. Truist Financial dropped their target price on shares of Teleflex from $260.00 to $250.00 and set a “hold” rating for the company in a research note on Monday, February 27th. Morgan Stanley boosted their target price on shares of Teleflex from $236.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Friday, January 6th. Stephens boosted their target price on shares of Teleflex from $280.00 to $295.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 28th. Finally, Raymond James boosted their target price on shares of Teleflex from $231.00 to $259.00 and gave the stock an “outperform” rating in a research note on Friday, February 24th. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $271.69.

Teleflex Price Performance

Shares of Teleflex stock opened at $223.03 on Monday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.43 and a current ratio of 2.43. The firm’s 50-day simple moving average is $242.83 and its 200-day simple moving average is $229.19. Teleflex has a twelve month low of $182.65 and a twelve month high of $356.72. The firm has a market cap of $10.47 billion, a P/E ratio of 29.04, a price-to-earnings-growth ratio of 2.34 and a beta of 0.98.

Teleflex (NYSE:TFX – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The medical technology company reported $3.52 EPS for the quarter, beating analysts’ consensus estimates of $3.44 by $0.08. The firm had revenue of $758.00 million for the quarter, compared to analyst estimates of $760.29 million. Teleflex had a net margin of 13.01% and a return on equity of 15.87%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.60 earnings per share. As a group, research analysts expect that Teleflex will post 13.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Teleflex

A number of institutional investors and hedge funds have recently modified their holdings of TFX. General Partner Inc. bought a new stake in shares of Teleflex during the fourth quarter worth approximately $28,000. First Horizon Advisors Inc. grew its holdings in Teleflex by 60.0% during the fourth quarter. First Horizon Advisors Inc. now owns 128 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the period. Ronald Blue Trust Inc. acquired a new position in Teleflex during the second quarter valued at approximately $34,000. Lazard Asset Management LLC grew its holdings in Teleflex by 9,000.0% during the third quarter. Lazard Asset Management LLC now owns 182 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 180 shares during the period. Finally, Wipfli Financial Advisors LLC acquired a new position in Teleflex during the third quarter valued at approximately $55,000. 93.82% of the stock is owned by institutional investors.

About Teleflex

(Get Rating)

Teleflex, Inc provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.